Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension

Journal of Hepatology

Volumn 37, Issue 6, 2002, Pages 773-780

  Croquet, Vincent ^a   Moal, Frédéric ^a   Veal, Nary ^a   Wang, Jianhua ^a   Oberti, Frédéric ^a   Roux, Jérôme ^b   Vuillemin, Eric ^a   Gallois, Yves ^b   Douay, Olivier ^b   Chappard, Daniel ^b   Calès, Paul ^a,c  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Angiotensin II; Angiotensin II receptor antagonist; Hemodynamics; Liver fibrosis; Losartan; Portal hypertension; Rat

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; CARBON TETRACHLORIDE; HYALURONIC ACID; HYDROXYPROLINE; LOSARTAN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FIBROGENESIS; HEMODYNAMICS; LIVER BLOOD FLOW; LIVER FIBROSIS; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; ANIMAL; BILE DUCT; BLOOD; DIURESIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; LIGATION; LIVER; LIVER CIRRHOSIS; PATHOLOGY; SPLANCHNIC BLOOD FLOW; SPRAGUE DAWLEY RAT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; BILE DUCTS; BILIRUBIN; CARBON TETRACHLORIDE; DIURESIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; HYPERTENSION, PORTAL; LIGATION; LIVER; LIVER CIRRHOSIS; LOSARTAN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; SPLANCHNIC CIRCULATION;

EID: 0036893741     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00307-0     Document Type: Article

References (44)

1. Wilkinson SP, Williams R. Renin-angiotensin-aldosterone system in cirrhosis. Gut 1980;21:545-554.
2. Ballet F, Chretien Y, Rey C, Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther 1988;244:233-235.
3. Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-Lopez F, Rodes J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981;11:221-229.
4. Campbell KA, Wu YP, Sitzmann JV. Angiotensin II increases porto-systemic collateral resistance in portal hypertension. J Surg Res 1991;51:181-185.
5. Goodfriend TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654.
6. Laragh JH, Angers M, Kelly WG, Lieberman S. Hypotensive agents and pressor substances: The effects of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. J Am Med Assoc 1960;174:234-240.
7. Bataller R, Ginès P, Nicolas JM, Görbig MN, Garcia-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-1156.
8. Pinzani M, Falli P, Ruocco C, Casini A, Milani S, Baldi E, et al. Fatstoring cells as liver specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992;90:642-646.
9. Rockey D. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997;25:2-5.
10. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29:334-339.
11. Klein CG, Kalk JF, Klein CP. Long term effect of losartan, an angiotensin II receptor antagonist, on portal pressure and intrahepatic resistance in cirrhosis of the liver. J Hepatol 1999;30:84A.
12. Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution. Gastroenterology 1999;117:740-742.
13. Gonzalez-Abraldes J, Albillos A, Banares R, Ruiz Del Arbol L, Moitinho E, Rodriguez C, et al. Randomized comparison of long-term losartan vs. propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-388.
14. Debernardi-Venon W, Barletti C, Alessandria C, Marzano A, Baronio M, Todros L, et al. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci 2002;47:401-404.
15. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995;47:1285-1294.
16. Youn TJ, Kim HS, Oh BH. Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: Effects of angiotensin converting inhibition and angiotensin II type 1 receptor blockade. Basic Res Cardiol 1999;94:246-253.
17. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000;342:1350-1358.
18. Campistol JM, Inigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F, et al. Losartan decreases plasma levels of TGF-betal in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-719.
19. Oberti F, Vuillemin E, Fort J, Calès P. Modèles expérimentaux d'hypertension portale. Gastroenterol Clin Biol 2000;24:896-901.
20. Gall JA, Bhathal PS. A quantitative analysis of the liver following ligation of the common bile duct. Liver 1990;10:116-125.
21. Beck PL, Lee SS. Vitamin K1 improves survival in bile-duct-ligated rats with cirrhosis. J Hepatol 1995;23:235.
22. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists. Hypertension 1990;15:459-468.
23. Chan P, Liu JC, Tong YC, Chen YJ, Wang CC, Tomlinson B, et al. Effects of losartan on the sexual behavior of male rats. Pharmacology 1999;58:132-139.
24. Braillon A, Broby MJ. A simple method for chronic cannulation of the portal vein in intact unrestrained rats. Am J Physiol 1988;255:G191-G193.
25. Calès P, Oberti F, Veal N, Fort J, Kaassis M, Moal F, et al. Splenorenal shunt blood flow by transit-time ultrasound as an index of collateral circulation in portal hypertensive rats. Hepatology 1998;28:1269-1274.
26. Veal N, Moal F, Wang J, Vuillemin E, Oberti F, Roy E, et al. New method of cardiac output measurement using ultrasound velocity dilution in rats. J Appl Physiol 2001;91:1274-1282.
27. Pilette C, Rousselet M, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. Histopathological evaluation of liver fibrosis: Quantitative image analysis vs. semi-quantitative scores. Comparison with serum markers. J Hepatol 1998;28:439-446.
28. Jamall IS, Finelli VN, Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981;112:70-75.
29. Fort J, Oberti F, Pilette C, Veal N, Gallois Y, Douay O, et al. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 1998;28:1525-1531.
30. Veal N, Oberti F, Moal F, Vuillemin E, Fort J, Kaassis M, et al. Spleno-renal shunt blood flow is an accurate index of collateral circulation in different models of portal hypertension and after pharmacological changes in rats. J Hepatol 2000;32:434-440.
31. Calès P, Braillon A, Jiron ML, Lebrec D. Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis, lack of correlation with oesophageal varices and gastrointestinal bleeding. Effect of propranolol. J Hepatol 1984;1:37-46.
32. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121:389-395.
33. Navasa M, Chesta J, Bosch J, Rodés J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Gastroenterology 1989;96:1110-1118.
34. Christ DD, Wong PC, Wong YN, Hart SD, Quon CY, Lam GN. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. J Pharmacol Exp Ther 1994;268:1199-1205.
35. Bomzon A, Rosenberg M, Gali D, Binah O, Mordechovitz D, Better OS, et al. Systemic hypotension and decreased pressor response in dogs with chronic bile duct ligation. Hepatology 1986;6:595-600.
36. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999;48:2066-2073.
37. Ju H, Dixon IM. Extracellular matrix and cardiovascular diseases. Can J Cardiol 1996;12:1259-1267.
38. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001;35:376-385.
39. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Angiotensin-II receptor interaction is a major regulation for liver fibrosis development in rats. Hepatology 2001;34:745-750.
40. Yoshiji H. Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, et al. The inhibition of angiotensin-I converting enzyme by perindopril decreased the liver fibrosis development in choline-deficient rats. J Hepatol 2002;37:22-30.
41. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, et al. Angiotensin converting enzyme inhibition attenuates the development of rat hepatic fibrosis. Gastroenterology 2001;121:148-155.
42. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-833.
43. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643-649.
44. Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: Implications for therapy. Gastroenterology 2000;118:1261-1265.